<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00193115</url>
  </required_header>
  <id_info>
    <org_study_id>SCRI BRE 69</org_study_id>
    <secondary_id>11251</secondary_id>
    <nct_id>NCT00193115</nct_id>
  </id_info>
  <brief_title>Docetaxel Followed by Doxorubicin Plus Cyclophosphamide for Node Positive or High-Risk Primary Breast Cancer</brief_title>
  <official_title>Phase II Pilot Trial of Dose-Dense Docetaxel Followed by Doxorubicin Plus Cyclophosphamide (T-AC) Given as Adjuvant or Neoadjuvant Treatment for Women With Node Positive or High-Risk Primary Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SCRI Development Innovations, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>SCRI Development Innovations, LLC</source>
  <brief_summary>
    <textblock>
      This protocol will evaluate the feasibility and toxicity of dose-dense docetaxel followed by&#xD;
      doxorubicin and cyclophosphamide with support given as adjuvant or neoadjuvant treatment of&#xD;
      women with node positive and high risk breast cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Upon determination of eligibility, patients will receive:&#xD;
&#xD;
      Neoadjuvant Docetaxel + Doxorubicin + Cyclophosphamide + Surgery&#xD;
&#xD;
      Adjuvant patients will enter the study after surgery and receive Docetaxel+ Doxorubicin +&#xD;
      Cyclophosphamide. Patients treated with lumpectomy will undergo postoperative radiation&#xD;
      therapy after completion of chemotherapy. Patients with positive estrogen and/or progesterone&#xD;
      receptors will begin anti-estrogen therapy after the last course of chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">June 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment-related toxicities</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
  </secondary_outcome>
  <enrollment>32</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxorubicin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be included in this study, you must meet the following criteria:&#xD;
&#xD;
          -  Histologically proven breast cancer&#xD;
&#xD;
          -  Females, age greater than 18 years&#xD;
&#xD;
          -  Ability to perform activites of daily living with minimal assistance&#xD;
&#xD;
          -  Normal cardiac function&#xD;
&#xD;
          -  Adequate bone marrow, liver and kidney&#xD;
&#xD;
          -  Signed informed consent prior to beginning specific protocol procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        You cannot participate in this study if any of the following apply to you:&#xD;
&#xD;
          -  Prior systemic anticancer therapy for breast cancer&#xD;
&#xD;
          -  Prior anthracycline or taxane based chemotherapy for any malignancy&#xD;
&#xD;
          -  Pregnant or breast-feeding women.&#xD;
&#xD;
          -  Pre-existing moderate to severe motor or sensory neurotoxicity&#xD;
&#xD;
          -  Other serious illness or medical condition&#xD;
&#xD;
        Please note: There are additional inclusion/exclusion criteria. The study center will&#xD;
        determine if you meet all of the criteria. If you do not qualify for the trial, study&#xD;
        personnel will explain the reasons. If you do qualify, study personnel will explain the&#xD;
        trial in detail and answer any questions you may have.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denise A. Yardley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>SCRI Development Innovations, LLC</affiliation>
  </overall_official>
  <link>
    <url>http://cigjournals.metapress.com/content/a801t38m78tvw61w/fulltext.pdf</url>
    <description>Published article in Clinical Breast Cancer</description>
  </link>
  <results_reference>
    <citation>Yardley DA, Burris HA 3rd, Farley CP, Barton JH, Peacock NW, Spigel DR, Greco FA, Hainsworth JD. A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer. Clin Breast Cancer. 2008 Jun;8(3):242-8. doi: 10.3816/CBC.2008.n.027.</citation>
    <PMID>18650154</PMID>
  </results_reference>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>August 3, 2010</last_update_submitted>
  <last_update_submitted_qc>August 3, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 4, 2010</last_update_posted>
  <responsible_party>
    <name_title>Denise A. Yardley, M.D.</name_title>
    <organization>Sarah Cannon Research Institute</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

